Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Olanzapine Glenmark

Olanzapine Glenmark 2.5 mg tablets · Abschnitt 4.8 · PDF-Seite 8–9

HOS-210974 · Präparat HOS-154617

Dysarthria Stuttering11 Restless Legs Syndrome11 Cardiac disorders Bradycardia Ventricular QTc prolongation (see tachycardia/fibrillation, section 4.4) sudden death (see section 4.4)11 Vascular disorders Orthostatic Thromboembolism hypotension10 (including pulmonary embolism and deep vein thrombosis) (see section 4.4) Respiratory, thoracic and mediastinal disorders 8  Epistaxis9 Gastrointestinal disorders Mild, transient Abdominal Pancreatitis11 anticholinergic distension9 effects including Salivary constipation and hypersecretion11 dry mouth Hepatobiliary disorders Transient, Hepatitis (including asymptomatic hepatocellular, elevations of cholestatic or mixed hepatic liver injury)11 aminotransferases (ALT, AST), especially in early treatment (see section 4.4) Skin and subcutaneous tissue disorders Rash Photosensitivity Drug reaction Reaction Alopecia with Eosinophilia and Systemic Symptoms (DRESS) Musculoskeletal and connective tissue disorders Arthralgia9 Rhabdomyolysis11 Renal and urinary disorders Urinary incontinence, urinary retention Urinary hesitation11 Pregnancy, puerperium and perinatal conditions Drug withdrawal syndrome neonatal (see section 4.6) Reproductive system and breast disorders Erectile dysfunction Amenorrhea Priapism12 in males Breast enlargement Decreased libido in Galactorrhea in males and females females Gynaecomastia/breast enlargement in males General disorders and administration site conditions Asthenia Fatigue Oedema Pyrexia10 Investigations Elevated Increased alkaline Increased total plasma phosphatase10 bilirubin prolactin High creatine levels8 phosphokinase11

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.